Hua Medicine (Shanghai) Ltd.
HKSE: 2552.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Li Chen
- Employees
- 168
- Headquarters
- Shanghai, China
- IPO year
- 2018
- Market cap
- HK$3.3B
- Website
- https://www.huamedicine.com
Loading 2552…
Loading profile data…Frequently asked questions about 2552
What does Hua Medicine (Shanghai) Ltd. (2552.HK) do?
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinic...
Where does 2552.HK trade?
Hua Medicine (Shanghai) Ltd. (2552.HK) trades on the Hong Kong Stock Exchange.
What sector is 2552.HK in?
Hua Medicine (Shanghai) Ltd. (2552.HK) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Hua Medicine (Shanghai) Ltd.?
Li Chen is the chief executive officer of Hua Medicine (Shanghai) Ltd. (2552.HK).
Where is Hua Medicine (Shanghai) Ltd. headquartered?
Hua Medicine (Shanghai) Ltd. is headquartered in China.
Does 2552.HK pay a dividend?
Hua Medicine (Shanghai) Ltd. (2552.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2552.HK go public?
Hua Medicine (Shanghai) Ltd. (2552.HK) completed its initial public offering in 2018.